– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 Carlsbad, CA, Sept. 06, 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results